Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE 1: Vyepti in Frequent Episodic Migraine
NCT02559895Phase 3Completed
- Sponsor
- Alder Biopharmaceuticals
- Start
- Sep 2015
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of eptinezumab in migraine (4 arms), sponsored by Alder Biopharmaceuticals. Primary endpoint: Change From Baseline in Monthly Migraine Days at 12 weeks. Started Sep 2015; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02559895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02559895.